Jefferies reiterates Buy on Nektar stock after alopecia trial data By Investing.com

Nektar reported 52-week Phase 2 data for Rezpeg showing about 28% of patients achieved SALT scores below 20, above management’s prior 20-25% expectation and in line with Oppenheimer’s 25-30% best-case view. Jefferies reiterated Buy with a $121 target, Oppenheimer kept Outperform and $140, and Wedbush initiated Neutral with a $70 target, reflecting improving but still mixed analyst sentiment. The company will hold an end-of-Phase 2 meeting in Q2 and release 24-week off-treatment data in Q4.

Analysis

NKTR is transitioning from a story stock into a data-validation trade, but the market is still pricing in a much cleaner regulatory and commercial path than the evidence supports. The important second-order effect is that a credible mid-20s efficacy signal in a crowded immunology space can re-rate the platform only if durability survives the off-treatment readout; without that, the current move risks becoming a short squeeze around a fundamentally binary catalyst sequence. The next leg is less about the headline response rate and more about whether responders persist once dosing stops, because that determines whether this becomes a chronic biologic franchise or a transient induction therapy.

Competitive dynamics are also more nuanced than the obvious “better than low-dose benchmark” framing. If NKTR’s profile is validated, the real pressure lands on earlier-line dermatology biologics and JAKs by shifting physician willingness toward a differentiated tolerability/maintenance narrative, but if the data merely match existing comparators, reimbursement and formulary access become the gating item rather than efficacy. That matters because the market opportunity is likely to be won on persistence and safety differentiation, not peak SALT response alone, especially in a disease where switching costs are low and patient churn is high.

The contrarian setup is that the stock may be over-earned on intermediate data: a favorable Phase 2 still leaves a long runway of proof points, and the current valuation already discounts a meaningful probability of success. The key reversal trigger is not failure, but ambiguity — if the Q4 off-treatment data show erosion of response or if the end-of-Phase-2 meeting pushes timelines out, the multiple can compress quickly even without a true clinical miss. On the other hand, a clean durability read plus a credible path to Phase 3 design could extend the rerating for several months because the stock is now owned more as an event-driven biotech than as a classic platform name.

Key Decisions for Investors

• Take profits on existing NKTR longs into strength ahead of the Q2 end-of-Phase-2 meeting; use a trailing stop on 15-20% downside from current levels because valuation is now heavily expectation-loaded.
• For tactical upside, buy NKTR call spreads into the Q2 catalyst with a 1-3 month tenor; cap premium given the binary risk that durability data disappoints and the rerating reverses quickly.
• If you want exposure to the thematic without single-name clinical risk, pair long a diversified dermatology commercializer against short NKTR post-rally; this isolates the gap between validated cash flow and speculative pipeline optionality.
• Set a calendar trade around Q4 off-treatment data: add only if response durability holds, otherwise fade the name on any sign of response attrition because the market will likely de-rate the platform on maintenance uncertainty.
• For risk-managed longs, consider using a collar on NKTR rather than outright stock; implied volatility should remain elevated into the next readout, making downside protection relatively cheap versus owning the full drawdown.